Drug intelligence / Profile preview

MT020

Development stage: Preclinical
Lead developer: Suzhou Maximum Bio-tech
Modality: Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

MT020 is an allogeneic CAR-T cell therapy candidate developed by T-Maximum Pharmaceutical for the treatment of B-cell-related autoimmune diseases. It leverages a mature allogeneic cell therapy platform, with a unique mechanism of action that targets specific pathways involved in autoimmune responses. The goal is to provide safer and more effective treatment options compared to existing therapies for B-cell-mediated autoimmunity. MT020 is not currently indicated for cancer but rather focuses on modulating immune function in autoimmune conditions[3][6][7].

Beyond the preview

Go deeper on MT020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT020.

Explore the full profile